Pharmaceuticals - Central America

Central America

The revenue in the Pharmaceuticals market in Central America is expected to reach US$2,032.00m in 2024.
Among the various markets, the largest market is Oncology Drugs, which is projected to have a market volume of US$318.40m in 2024.
Furthermore, the revenue in the Pharmaceuticals market is anticipated to exhibit an annual growth rate of 3.84% (CAGR 2024-2029), resulting in a market volume of US$2,453.00m by 2029.
In comparison to other countries worldwide, United States is expected to generate the highest revenue, amounting to US$630.30bn in 2024.
In Central America, the pharmaceutical market is experiencing a surge in demand for generic drugs due to their affordability and accessibility.

Key regions: United States, China, Germany, Japan, Europe

Definition:
The Pharmaceuticals market covers remedies used to cure, treat, prevent, and diagnose diseases. These small molecule drugs or biologic medical products may be called drugs, medications, or medicines. Prescription drugs and over-the-counter (OTC) drugs are both included. Depending on the regulations in each country, these products are provided by pharmacies, hospitals, physicians, and/or drug stores, and/or they can be bought elsewhere. They may be administered in the form of pills, capsules, gels, ointments, injections, infusions, lozenges, or aerosols/sprays.

Structure:
The market is subdivided into Oncology Drugs, Anti-Diabetes Drugs, Anti-Rheumatic Drugs, Vaccines, Dermatological Drugs, Antiviral Drugs, Immunosuppressants, Bronchodilator Drugs, Sensory Organ Drugs, Anti-Hypertensive Drugs, Anti-Coagulants, Anti-Fibrinolytic Drugs, Multiple Sclerosis Drugs, Lipid-Lowering Agents and Other Pharmaceuticals. The Pharmaceuticals market is organized in markets that cover drugs used in specific medical fields, i.e., medicines for a specific disesase or a certain type of medicine. They include original brands, biosimilars, generics, and orphan drugs.The Oncology Drugs market covers pharmaceutical products specifically developed for the treatment and management of various cancers. The Anti-Diabetes Drugs market covers medications designed to manage blood glucose levels and improve insulin sensitivity in individuals with diabetes. The market Anti-Rheumatic Drugs includes pharmaceuticals specifically developed to alleviate symptoms, reduce inflammation, and modify the progression of rheumatic diseases. The Dermatological Drugs market covers pharmaceuticals formulated to treat and manage a wide range of skin conditions such as eczema, acne, and rosacea. The Antiviral Drugs market includes medications designed to treat viral infections and reducing the severity and duration of symptoms. The Immunosuppressants market covers pharmaceuticals that suppress the immune system's activity. The Bronchodilator Drugs market covers pharmaceuticals designed to relax and widen the airways in the lungs. The Sensory Organ Drugs market covers pharmaceuticals targeting the treatment of disorders and conditions affecting sensory organs such as the eyes, ears and nose. The Anti-hypertensive Drugs market covers pharmaceuticals designed to lower blood pressure levels. The Anti-Coagulants Drugs market covers pharmaceuticals developed to prevent the formation of blood clots or to dissolve existing clots. The Anti-Fibrinolytics Drugs market covers pharmaceuticals designed to inhibit the breakdown of blood clots. The Multiple Sclerosis Drugs market covers pharmaceuticals aimed at managing and modifying the course of multiple sclerosis. The Lipid-Lowering Agents market covers pharmaceuticals developed to reduce levels of cholesterol and other lipids in the blood. The Other Pharmaceuticals market provides information on additional specialties that are not covered by the main markets.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novartis, Roche, Pfizer, Merck & Co, Johnson & Johnson, AbbVie, Sanofi.

Market

Region

Region comparison

Currency

Analyst Opinion

Central America, a region located between North and South America, has seen a steady growth in its pharmaceuticals market over the past few years.

Customer preferences: One of the primary drivers of this growth is the increasing demand for healthcare services in the region. With a growing population and an increase in the prevalence of chronic diseases, there is a greater need for pharmaceutical products. Additionally, the region's middle class is expanding, and with it, their purchasing power. This has led to a greater demand for higher quality and more expensive medications.

Trends in the market: Each country in Central America has its own unique pharmaceutical market, with varying trends. For example, in Guatemala, there has been a growing trend towards the use of generic drugs, as they are more affordable for the majority of the population. In contrast, in Costa Rica, there has been a greater demand for branded drugs, as the population has a higher disposable income.

Local special circumstances: One of the challenges facing the pharmaceutical market in Central America is the lack of regulation and oversight. This has led to a proliferation of counterfeit drugs, which can be dangerous for consumers. Additionally, there is a lack of investment in research and development, which has hindered the development of new and innovative drugs.

Underlying macroeconomic factors: Despite these challenges, there are several macroeconomic factors that are driving the growth of the pharmaceutical market in Central America. One of these is the increasing investment in healthcare infrastructure by governments in the region. This has led to a greater availability of healthcare services and an increase in demand for pharmaceutical products. Additionally, the region's proximity to the United States has led to an increase in foreign investment, which has helped to stimulate the market. Finally, the region's favorable trade agreements with the United States and other countries have made it an attractive location for pharmaceutical companies looking to expand their operations.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.